- Quarter end
- 31 Mar 2024
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 6 May 2024
- Managers listing it
- 13
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q4 2023 and Q1 2024; 12 listed it in both
- Shares listed
- 123,145,710
- combined, among listed positions
- Reported value
- $5.3bn
- combined, at the quarter end
Among the 93 comparable managers: 5 buyers (opened or added shares) and 7 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing GSK in Q1 2024
13 of 13 holders
Largest increases and reductions, by shares
Increases
- Fidelity (FMR LLC)existing position · 24,581,222 shares now+5,215,091
- Acadian Asset Management LLCexisting position · 2,219,798 shares now+1,426,935
- Holocene Advisors LPexisting position · 8,719,644 shares now+495,096
- ExodusPoint Capital Management LPexisting position · 311,337 shares now+74,528
Reductions
- Arrowstreet Capital LPexisting position · 2,106,272 shares now-2,713,681
- T. Rowe Price Associates Incexisting position · 11,465,413 shares now-1,353,545
- Renaissance Technologies LLCexisting position · 1,793,393 shares now-971,800
- Dodge & Coxexisting position · 68,862,308 shares now-164,485
- Quantbot Technologies LPexisting position · 44,556 shares now-100,156
New positions and exits
New (0)
No new position among listed positions.
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2022 | 1 | $19m | n.a. | n.a. |
| Q3 2022 | 18 | $3.9bn | n.a. | n.a. |
| Q4 2022 | 18 | $4.9bn | n.a. | n.a. |
| Q1 2023 | 13 | $4.4bn | n.a. | n.a. |
| Q2 2023 | 13 | $4.3bn | n.a. | n.a. |
| Q3 2023 | 16 | $4.5bn | n.a. | n.a. |
| Q4 2023 | 13 | $4.5bn | 6 | 7 |
| Q1 2024 | 13 | $5.3bn | 5 | 7 |
| Q2 2024 | 10 | $4.6bn | 6 | 4 |
| Q3 2024 | 10 | $4.9bn | 6 | 3 |
| Q4 2024 | 13 | $4.9bn | 11 | 2 |
| Q1 2025 | 11 | $6.3bn | 7 | 6 |
| Q2 2025 | 10 | $6.2bn | 8 | 3 |
| Q3 2025 | 11 | $7.5bn | 6 | 5 |
| Q4 2025 | 11 | $8.8bn | 15 | 13 |
| Q1 2026 | 9 | $9.1bn | 9 | 19 |
| Q2 2026 | 11 | $7.5bn | 15 | 12 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
GSK and LLY →GSK and JNJ →GSK and VRTX →Choose a stock to compare with GSK →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own GSK, latest filings →Back to the 13F Explorer →